Abstract
The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study is a nationwide, prospective, multicenter observational study that was designed to enroll hypertensive Japanese patients (>30,000 subjects). The patients in this study received treatment with open-label losartan, an angiotensin II receptor antagonist, for a maximum of 5 years. This report summarizes the study protocol and the baseline characteristics of the patients. Between June 2000 and May 2002, patients were screened in all 47 prefectures around Japan. Among the 31,515 patients screened, 31,048 patients were enrolled in this study and treated with losartan at a daily dose of 25–50 mg. These patients were 62.4±12.1 years old (mean±SD) and the mean clinic systolic/diastolic blood pressure (BP) values were 165.3±17.3/94.3±11.7 mmHg (mean±SD). The complications of hyperlipidemia, diabetes mellitus, cardiovascular disease, and cerebrovascular disease were also present in 38.5%, 13.1%, 8.0%, and 4.4% of patients, respectively. Regarding the World Health Organization classification, grade 2 hypertension was most frequent in this patient cohort. Nearly 10,000 patients agreed to perform home BP monitoring and report details regarding their lifestyles at baseline. Among the patients, 4.2% had white coat hypertension at the baseline. The J-HEALTH study is expected to provide valuable information about the significance of clinic and home BP control and home BP monitoring for the management of hypertension in Japanese patients.
Similar content being viewed by others
Article PDF
References
World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Fujiwara T, Nishimura T, Ohkubo T, Imai Y : Rationale and design of HOMED-BP Study: Hypertension Objective treatment based on Measurement by Electrical Devices of Blood Pressure Study. Blood Press Monit 2002; 7: 77–82.
The ALLHAT Officers and Coordination for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Neal B, MacMahon S, Chapman N : Effects of ACE inhibitors, calcium antagonists, and other blood pressure–lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955–1964.
Japanese Society of Hypertension : Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Brenner BM, Cooper ME, Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Lindholm LH, Ibbsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.
Dickstein K, Kjekshus J : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–760.
Pitt B, Poole-Wilson PA, Segal R, et al: Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.
Ueshima H : Changes in dietary habit, cardiovascular risk factors and mortality in Japan. Acta Cardiol 1990; 45: 311–327.
Khor GL : Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001; 10: 76–80.
Tsuji I, Imai Y, Nagai K, et al: Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens 1997; 10: 409–418.
Tachibana R, Tabara Y, Kondo I, et al: Home blood pressure is a better predictor of carotid atherosclerosis than office blood pressure in community-dwelling subjects, Hypertens Res 2004; 27: 633–639.
Ohkubo T, Obara T, Funahashi J, et al: Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res 2004; 27: 755–763.
Thijs L, Staessen JA, Celis H, et al: Reference values for self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med 1998; 158: 481–488.
Kubo M, Kiyohara Y, Kato I, et al: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349–2354.
Current Population Estimates as of October 1, 2004. Tokyo, Ministry of Internal Affaires and Communications, Statistics Bureau, 2004.
Iida M, Ueda K, Okayama A, et al: Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese—Nippon data 80. J Hum Hypertens 2003; 17: 851–857.
Konishi M, Iso H, Iida M, et al: Trends for coronary heart disease and its risk factors in Japan: epidemiologic and pathologic studies. Jpn Circ J 1990; 54: 428–435.
Lewington S, Clarke R, Oizilbash N, Peto R, Collins R : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Bulpitt CJ, Beckett NS, Cooke J, et al: Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–2417.
Gueyffier F, Bulpitt C, Boissel JP, et al: Antihypertensive drugs in very old people: meta-analysis of randomized controlled trials. Lancet 1999; 353: 793–796.
Arima H, Tanizaki Y, Kiyohara Y, et al: Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med 2003; 163: 361–366.
Celis H, Den Hond E, Staessen JA : Self-measurement of blood pressure at home in the management of hypertension. Clin Med Res 2005; 3: 19–26.
Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R : Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846–853.
Den Hond E, Celis H, Vandenhoven G, O'Brien E, Staessen JA : Determinants of white-coat syndrome assessed by ambulatory blood pressure of self-measured home blood pressure. Blood Press Monit 2003; 8: 37–40.
Den Hond E, Celis H, Fagard R, et al: Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens 2003; 21: 717–722.
Hozawa A, Ohkubo T, Kikuya M, et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama Study. Hypertens Res 2002; 25: 57–63.
Celis H, Fagard RH : White-coat hypertension: a clinical review. Eur J Intern Med 2004; 15: 348–357.
Bobrie G, Chatellier G, Genes N, et al: Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naritomi, H., Fujita, T., Ito, S. et al. Design and Baseline Characteristics of an Observational Study in Japanese Patients with Hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH). Hypertens Res 30, 807–814 (2007). https://doi.org/10.1291/hypres.30.807
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.807
Keywords
This article is cited by
-
Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan
Hypertension Research (2012)